Tempus AI (TEM) and Merck (MRK) announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and potentially broader therapeutic portfolios. Under the terms of the agreement, Merck will use Tempus’ de-identified data along with Tempus’ Lens Platform and Workspaces environment.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade TEMPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI price target lowered to $70 from $85 at Morgan Stanley
- XAIX, AGIX: Two Best Artificial Intelligence (AI) ETFs to Buy Now
- Cathie Wood’s ARK Investment buys 213K shares of Tempus AI today
- Tempus AI price target raised to $68 from $59 at Baird
- Tempus AI price target lowered to $60 from $85 at Stifel